News | May 27, 2025
Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Allopurinol is used to prevent or lower high uric acid levels in the blood
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Subscribe To Our Newsletter & Stay Updated
